Clinical Trial: A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Melanoma
Study Type: INTERVENTIONAL
Official Title: A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants
Brief Summary:
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma.Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Read more